4
Ossenkoppele, Gert Jan, Stussi, Georg, Maertens, Johan, van Montfort, Kees, Biemond, Bart J., Breems, Dimitri, Ferrant, August, Graux, Carlos, de Greef, Georgine E., Halkes, C. J. M., Hoogendoorn, Mels, Hollestein, Rene M., Jongen-Lavrencic, Mojca, Levin, Mark-David, van de Loosdrecht, Arjan A., Kooij, Marinus van Marwijk, van Norden, Yvette, Pabst, Thomas, Schouten, Harry C., Vellenga, Edo, Verhoef, Gregor E. G., de Weerdt, Okke, Wijermans, Pierre, Passweg, Jakob R., Lowenberg, Bob
Veröffentlicht in: Ossenkoppele , G J , Stussi , G , Maertens , J , van Montfort , K , Biemond , B J , Breems , D , Ferrant , A , Graux , C , de Greef , G E , Halkes , C J M , Hoogendoorn , M , Hollestein , R M , Jongen-Lavrencic , M , Levin , M-D , van de Loosdrecht , A A , Kooij , M V M , van Norden , Y , Pabst , T , Schouten , H C , Vellenga , E , Verhoef , G E G , de Weerdt , O , Wijermans , P , Passweg , J R & Lowenberg , B 2012 , ' Addition of bevacizumab to chemotherapy in acute myeloid leukemia at older age: a randomized phase 2 trial of the Dutch-Belgian Cooperative Trial Group for Hemato-Oncology (HOVON) and the Swiss Group for Clinical Cancer Research (SAKK) ' , Blood , vol. 120 , no. 24 , pp. 4706-4711 . https://doi.org/10.1182/blood-2012-04-420596;
2012
5